Health
STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
Publication: STAT
Author: Adam Feuerstein
Source published: 16/11/2026, 13:00:00 UTC
Briefing created: 16/11/2026, 13:31:03 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/11/2026, 13:06:24 UTC.
Briefings
A randomized Phase 3 study involving 367 patients with intermediate-risk bladder cancer found that the cretostimogene immunotherapy from CG Oncology reduced the risk of tumor recurrence by 68% compared to standard medical practice. The treatment involves infusing a virus-engineered protein directly into the bladder via catheter, which replicates, kills cancer cells, and breaks them open. Results were announced Monday, potentially changing treatment protocols for this specific disease stage.
Key points
- The study enrolled 367 patients with intermediate-risk bladder cancer, a localized form typically removed surgically, and monitored them every three months.
- Cretostimogene, derived from a common cold virus engineered to target specific bladder tumor mutations, was administered directly into the bladder via catheter.
Context
This finding addresses a critical need in bladder cancer management, where standard surgical removal often leaves residual disease that can recur. The reduction in recurrence risk by 68% represents a significant clinical improvement for patients who might otherwise lose bladder function through repeated surgeries.
Limitations
The evidence is limited to a single randomized Phase 3 study with 367 participants. Results are based on a snapshot of data collected over a specific period, and the long-term safety profile of the virus-engineered protein in this specific population remains untested.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/11/2026, 13:31:03 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifiwc2suehwmzda3nwx3cco5gjqjngguzhzjn32k4mpkykjtvjpsq